Curcumin Synergizes with Cisplatin to Inhibit Colon Cancer through Targeting the MicroRNA-137-Glutaminase Axis

• Published in: Current medical science Vol. 42; no. 1; pp. 108 - 117
• Main Authors: Fan, Wen-hui, Wang, Feng-chun, Jin, Zhi, Zhu, Lin, Zhang, Jian-xin
• Format: Journal Article
• Language: English
• Published: Wuhan Huazhong University of Science and Technology 01.02.2022; Department of Traditional Chinese Medicine,the Second Hospital of Shandong University,Jinan 250014,China%Department of Vascular Surgery,the Second Hospital of Shandong University,Jinan 250014,China
• Subjects: Antineoplastic Agents - pharmacology; Cell Line, Tumor; Cisplatin - pharmacology; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - enzymology; Colorectal Neoplasms - metabolism; Curcumin - pharmacology; Glutaminase - drug effects; Humans; Medicine; Medicine & Public Health; MicroRNAs - drug effects; glutamine metabolism; cisplatin resistant; glutaminase; microRNA-137; curcumin
• ISSN: 2096-5230; 1672-0733; 2523-899X; 1993-1352
• DOI: 10.1007/s11596-021-2469-0

Objective Colorectal cancer (CRC) is one of the most lethal and prevalent malignancies world-wide. Currently, surgery, radiotherapy and chemotherapy are clinically applied as common approaches for CRC patients. Cisplatin is one of the most frequently used chemotherapy drugs for diverse cancers. Although chemotherapeutic strategies have improved the prognosis and survival of cancer patients, development of cisplatin resistance has led to cancer recurrence. Curcumin, isolated from turmeric, has been used as an effective anti-cancer agent. However, the molecular mechanisms for curcumin-mediated cisplatin sensitivity of CRC have not been elucidated. This study aimed to investigate the effects of curcumin treatment on cisplatin-resistant CRC cells. Methods Expression levels of miRNAs and mRNAs were determined by qRT-PCR. Protein expression levels were detected by Western blotting. Cell responses to curcumin treatments were evaluated by MTT assay, Clonogenic assay and Annexin V apoptosis assay. The glutamine metabolism of colon cancer cells was assessed by glutamine uptake and glutaminase (GLS) activity. The binding of miR-137 on 3′ UTR of GLS was validated by Western blotting and luciferase assay. Results Results demonstrated that curcumin significantly synergized with cisplatin (combination index <1) to suppress proliferation of colon cancer cells compared with curcumin or cisplatin alone. Moreover, from the established cisplatin-resistant cell line (HT-29), glutamine metabolism was remarkedly elevated in cisplatin-resistant CRC cells that displayed a glutamine addictive phenotype. Furthermore, curcumin treatments attenuated glutamine metabolism in colon cancer cells. Under low glutamine supply, colon cancer cells showed less sensitivity to curcumin. Using a microRNA (miRNA) microArray assay, miR-137, a tumor suppressor in colon cancer, was significantly induced by curcumin treatments in CRC cells. Bioinformatics analysis and a luciferase assay illustrated miR-137 directly targeted the 3′ UTR of GLS mRNA. Rescue experiments demonstrated that miR-137-induced cisplatin sensitization was through targeting of GLS. Finally, curcumin treatment overcame cisplatin resistance through miR-137-mediated glutamine inhibition. Conclusion Collectively, these results indicate that curcumin could be clinically applied as an anti-chemoresistance approach against CRC by modulating miR-137-inhibited glutamine metabolism.